Ventripoint Diagnostics (TSX. V: VPT) (OTC: VPTDF) AI-driven medical imaging technology for cardio and cancer markets

February 27, 2019 admin CEO Interview, Healthcare Comments Off on Ventripoint Diagnostics (TSX. V: VPT) (OTC: VPTDF) AI-driven medical imaging technology for cardio and cancer markets

 

Discover Tomorrow’s Winning Stocks!
Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

Dr. George Adams, CEO

 

 

 

 

 

 

Ventripoint Diagnostics (TSX. V: VPT) (OTC: VPTDF) interview with Dr. George Adams, CEO, discussing the company’s innovative AI-driven medical imaging technology addressing the cardio and cancer markets. The company has recently entered commercialization stage, and Dr. Admas provides an updates on the sales pipeline, and future growth potential.

Investor Presentation

Ventripoint Presentation

 




Related Articles

CEO Interview

MGC Pharmaceuticals, LTD. (ASX: MXC) (OTC: MGCLF) Cannabis-based pharmaceuticals for major markets (revenue positive)

May 29, 2019 admin CEO Interview, Healthcare Comments Off on MGC Pharmaceuticals, LTD. (ASX: MXC) (OTC: MGCLF) Cannabis-based pharmaceuticals for major markets (revenue positive)

  Discover Tomorrow’s Winning Stocks! Thank you for subscribing. Something went wrong. Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox. […]

Newsmakers

Abeona Therapeutics (NASDAQ:ABEO) Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

April 20, 2018 admin Newsmakers Comments Off on Abeona Therapeutics (NASDAQ:ABEO) Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

NEW YORK and CLEVELAND, April 20, 2018 – Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European […]